ATE246937T1 - Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff - Google Patents
Verwendung von threalose zur stabilisierung von einem flüssigen impfstoffInfo
- Publication number
- ATE246937T1 ATE246937T1 AT00912734T AT00912734T ATE246937T1 AT E246937 T1 ATE246937 T1 AT E246937T1 AT 00912734 T AT00912734 T AT 00912734T AT 00912734 T AT00912734 T AT 00912734T AT E246937 T1 ATE246937 T1 AT E246937T1
- Authority
- AT
- Austria
- Prior art keywords
- liquid vaccine
- threalose
- stabilization
- vaccine composition
- liquid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000007788 liquid Substances 0.000 title abstract 3
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9903765A FR2791895B1 (fr) | 1999-03-23 | 1999-03-23 | Utilisation de trehalose pour stabiliser un vaccin liquide |
| PCT/FR2000/000730 WO2000056365A1 (fr) | 1999-03-23 | 2000-03-23 | Utilisation de trehalose pour stabiliser un vaccin liquide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE246937T1 true ATE246937T1 (de) | 2003-08-15 |
Family
ID=9543654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00912734T ATE246937T1 (de) | 1999-03-23 | 2000-03-23 | Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1163008B1 (de) |
| JP (1) | JP2002540079A (de) |
| AT (1) | ATE246937T1 (de) |
| AU (1) | AU3438900A (de) |
| CA (1) | CA2366869A1 (de) |
| DE (1) | DE60004496T2 (de) |
| DK (1) | DK1163008T3 (de) |
| ES (1) | ES2200845T3 (de) |
| FR (1) | FR2791895B1 (de) |
| PT (1) | PT1163008E (de) |
| WO (1) | WO2000056365A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1463097A (en) | 1996-01-04 | 1997-08-01 | Rican Limited | Helicobacter pylori bacterioferritin |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
| EP2172213B1 (de) | 2003-01-30 | 2013-04-03 | Novartis AG | Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen |
| PL1961426T3 (pl) | 2003-10-02 | 2012-03-30 | Gsk Vaccines S R L | Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
| MX2008014391A (es) * | 2006-05-12 | 2009-03-06 | Bharat Biotech Int Ltd | Una composicion util como vacuna. |
| PL2066344T3 (pl) | 2006-09-07 | 2011-10-31 | Glaxosmithkline Biologicals Sa | Skojarzona szczepionka zawierająca inaktywowany wirus polio |
| BRPI0810778A2 (pt) | 2007-05-02 | 2011-09-13 | Glaxosmithkline Biolog Sa | kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo |
| SI2198007T1 (en) | 2007-09-14 | 2018-04-30 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing Clostridium difficile A and B toxoids |
| EP2106788A1 (de) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Flüssige und lyophilisierte Formulierungen |
| BR112012009014B8 (pt) | 2009-09-30 | 2022-10-04 | Novartis Ag | Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica |
| CN102869378A (zh) | 2010-03-10 | 2013-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| GB201016969D0 (en) | 2010-10-08 | 2010-11-24 | Genome Res Ltd | Expression system |
| CA2777431A1 (en) | 2011-05-20 | 2012-11-20 | Nitto Denko Corporation | Pharmaceutical composition and method for producing the same |
| WO2013038375A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Methods for making saccharide-protein glycoconjugates |
| WO2013083753A2 (en) | 2011-12-07 | 2013-06-13 | Institut Pasteur | Identification of a swine parecho-like virus and applications |
| US10124051B2 (en) | 2012-05-22 | 2018-11-13 | Glaxosmithkline Biologicals Sa | Meningococcus serogroup X conjugate |
| FR2992656B1 (fr) * | 2012-07-02 | 2016-10-07 | Sanofi Pasteur | Procede de production d'antigenes haemophilus influenzae type b |
| CN104487086B (zh) * | 2012-07-07 | 2019-08-30 | 巴拉特生物技术国际有限公司 | 无动物源的不含酒精的疫苗组合物及其制备方法 |
| ES2848048T3 (es) | 2012-10-03 | 2021-08-05 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas |
| ES2677723T3 (es) * | 2012-12-28 | 2018-08-06 | Cellestis Limited | Un ensayo de la respuesta inmunológica mediada por células |
| US11612664B2 (en) | 2016-04-05 | 2023-03-28 | Gsk Vaccines S.R.L. | Immunogenic compositions |
| CA3033364A1 (en) | 2016-09-02 | 2018-03-08 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
| US11149255B2 (en) | 2016-09-06 | 2021-10-19 | Bioventures, Llc | Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors |
| EP3369431A1 (de) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Impfstoff |
| KR102549625B1 (ko) | 2017-03-03 | 2023-06-28 | 트레오스 바이오 리미티드 | 개인화된 면역원성 펩타이드 확인 플랫폼 |
| EP3370065A1 (de) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Immunogene peptide |
| MX2021002449A (es) | 2018-09-04 | 2021-08-05 | Treos Bio Ltd | Vacunas peptidicas. |
| GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
| CA3117867A1 (en) | 2018-11-06 | 2020-05-14 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| GB201908332D0 (en) | 2019-06-11 | 2019-07-24 | Univ Oxford Innovation Ltd | Assays and inhibitors of oxygen-dependent N-terminal oxidation |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| WO2021198705A1 (en) | 2020-04-03 | 2021-10-07 | Peptc Vaccines Limited | Coronavirus vaccine |
| WO2022268916A2 (en) | 2021-06-23 | 2022-12-29 | Ose Immunotherapeutics | Pan-coronavirus peptide vaccine |
| GB202109082D0 (en) | 2021-06-24 | 2021-08-11 | Univ Oxford Innovation Ltd | Polypeptides and uses thereof |
| WO2023148333A1 (en) | 2022-02-03 | 2023-08-10 | CeCaVa GmbH & Co. KG | Co-vaccination with cd4 and cd8 antigens |
| GB202208695D0 (en) | 2022-06-14 | 2022-07-27 | Univ Oxford Innovation Ltd | Antibacterials |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2748132A1 (de) * | 1977-10-27 | 1979-05-03 | Behringwerke Ag | Stabilisator fuer polysaccharid |
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
| ES2137310T3 (es) * | 1993-05-17 | 1999-12-16 | Akzo Nobel Nv | Vacuna contra una infeccion por streptococcus suis. |
| WO1995033488A1 (en) * | 1994-06-02 | 1995-12-14 | Quadrant Holdings Cambridge Limited | Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby |
| DE69738271T2 (de) * | 1996-09-26 | 2008-08-28 | Merck & Co., Inc. | Rotavirus-impfstoff |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
-
1999
- 1999-03-23 FR FR9903765A patent/FR2791895B1/fr not_active Expired - Fee Related
-
2000
- 2000-03-23 WO PCT/FR2000/000730 patent/WO2000056365A1/fr active IP Right Grant
- 2000-03-23 DK DK00912734T patent/DK1163008T3/da active
- 2000-03-23 AT AT00912734T patent/ATE246937T1/de not_active IP Right Cessation
- 2000-03-23 JP JP2000606269A patent/JP2002540079A/ja active Pending
- 2000-03-23 EP EP00912734A patent/EP1163008B1/de not_active Expired - Lifetime
- 2000-03-23 CA CA002366869A patent/CA2366869A1/en not_active Abandoned
- 2000-03-23 PT PT00912734T patent/PT1163008E/pt unknown
- 2000-03-23 DE DE60004496T patent/DE60004496T2/de not_active Expired - Fee Related
- 2000-03-23 ES ES00912734T patent/ES2200845T3/es not_active Expired - Lifetime
- 2000-03-23 AU AU34389/00A patent/AU3438900A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002540079A (ja) | 2002-11-26 |
| DE60004496T2 (de) | 2004-04-08 |
| CA2366869A1 (en) | 2000-09-28 |
| WO2000056365A1 (fr) | 2000-09-28 |
| ES2200845T3 (es) | 2004-03-16 |
| FR2791895A1 (fr) | 2000-10-13 |
| PT1163008E (pt) | 2003-12-31 |
| DK1163008T3 (da) | 2003-11-17 |
| EP1163008A1 (de) | 2001-12-19 |
| AU3438900A (en) | 2000-10-09 |
| EP1163008B1 (de) | 2003-08-13 |
| FR2791895B1 (fr) | 2001-06-15 |
| DE60004496D1 (de) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE246937T1 (de) | Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff | |
| UA93855C2 (ru) | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе | |
| IL210392A0 (en) | Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof | |
| DE69819332D1 (de) | VERBESSERTE ANTIKÖRPER GEGEN IgE UND VERFAHREN ZUR VERBESSERUNG VON ANTIKÖRPERN | |
| DE60100473D1 (de) | Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen | |
| DE69936948D1 (de) | Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten | |
| ATE394536T1 (de) | Textilweichmacherzusammensetzungen und verfahren zur stabilisierung von textilweichmacherzusammensetzungen | |
| EP1408986A4 (de) | Proteomimetische verbindungen und verfahren | |
| YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
| ATE543506T1 (de) | Methode zur stabilisierung von proteinen | |
| DE69431404D1 (de) | Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe | |
| DE69717413D1 (de) | Verfahren zur Gewichtsbestimmung von bogenförmigen Trägern | |
| GEP20043349B (en) | Methods of Controlling Cutworm Pests | |
| ATE220558T1 (de) | Verbessertes verfahren zur stabilisierung von proteinen | |
| DE60230456D1 (de) | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren | |
| DE60007657D1 (de) | Verfahren zur stabilisierung von siloxan-verbindungen | |
| DE69835813D1 (de) | Verfahren zur kultivierung von zellen und zur vermehrung von viren | |
| ATE424217T1 (de) | Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen | |
| ATE274185T1 (de) | Verfahren und zusammensetzungen zur trennung von biologischen makromolekülen | |
| DE69830156D1 (de) | Zusammensetzungen zur immunverstärkung von impfstoffen | |
| ATE505538T1 (de) | Dna-vektoren | |
| ATE340249T1 (de) | Produkt zur proteinstabilisierung von weinen | |
| SE9604439D0 (sv) | New receptor | |
| DE69805298D1 (de) | Verbessertes verfahren zur kryopreservierung von pferdeembryonen | |
| ATE359811T1 (de) | Verwendung von trehalose produzierenden prokaryotischen zellen als impfstoffe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1163008 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |